CD38 as a target of IB4 mAb carrying saporin-S6: design of an immunotoxin for ex vivo depletion of hematological CD38+ neoplasia.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Biological Regulators and Homeostatic Agents

• Publication date

  2005-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 16602630
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Toxicity of xanthine oxidoreductase to malignant B lymphocytes.

  2005cited by this paper
• The use of CD38 expression by monoclonal B lymphocytes as a prognostic factor in B-cell chronic lymphocytic leukemia.

  2004cited by this paper
• Retinoic acid-induced CD38 antigen as a target for immunotoxin-mediated killing of leukemia cells.

  2004cited by this paper
• Description, distribution, activity and phylogenetic relationship of ribosome-inactivating proteins in plants, fungi and bacteria.

  2004cited by this paper
• Immunotoxins and other conjugates: pre-clinical studies.

  2004cited by this paper
• CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells.

  2003cited by this paper
• Design and scaleup of downstream processing of monoclonal antibodies for cancer therapy: from research to clinical proof of principle.

  2003cited by this paper
• Peripheral blood CD38 expression predicts survival in B-cell chronic lymphocytic leukemia.

  2001cited by this paper
• Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin

  2001cited by this paper
• Immunotoxins Containing Recombinant Anti-CTLA-4 Single-Chain Fragment Variable Antibodies and Saporin: In Vitro Results and In Vivo Effects in an Acute Rejection Model1

  2001cited by this paper
• In vitro anti‐tumour activity of anti‐CD80 and anti‐CD86 immunotoxins containing type 1 ribosome‐inactivating proteins

  2000cited by this paper
• A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease.

  2000cited by this paper
• Schematic portrait of human CD38 and related molecules.

  2000cited by this paper
• CD38/CD31, a receptor/ligand system ruling adhesion and signaling in human leukocytes.

  2000cited by this paper
• Human CD38, a surface receptor, an enzyme, an adhesion molecule and not a simple marker.

  1999cited by this paper
• The relationship of HLA-DR, CD38 and CD71 markers to activation, proliferation and differentiation of some human leukemia and lymphoma cells.

  1998cited by this paper
• CD38 functions are regulated through an internalization step.

  1998cited by this paper
• CD38 is functionally dependent on the TCR/CD3 complex in human T cells

  1998cited by this paper
• Induction of apoptosis by ribosome‐inactivating proteins and related immunotoxins

  1996cited by this paper
• Detection of myeloma cells in the peripheral blood by flow cytometry.

  1996cited by this paper
• Therapy of human B‐cell lymphoma bearing scid mice is more effective with anti‐CD19‐and anti‐CD38‐saporin immunotoxins used in combination than with either immunotoxin used alone

  1995cited by this paper
• Immunotoxin therapy of hematological malignancies.

  1995cited by this paper
• Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-alpha.

  1994cited by this paper
• Positive selection of hematopoietic CD34+ stem cells provides 'indirect purging' of CD34- lymphoid cells and the purging efficiency is increased by anti-CD2 and anti-CD30 immunotoxins.

  1994cited by this paper
• Ribosome-inactivating proteins from plants.

  1993cited by this paper
• Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin.

  1992cited by this paper
• Involvement of the multilineage CD38 molecule in a unique pathway of cell activation and proliferation.

  1990cited by this paper
• Characterization of a murine monoclonal antibody specific for human early lymphohemopoietic cells.

  1984cited by this paper
• Ribosome-inactivating proteins from the seeds of Saponaria officinalis L. (soapwort), of Agrostemma githago L. (corn cockle) and of Asparagus officinalis L. (asparagus), and from the latex of Hura crepitans L. (sandbox tree).

  1983cited by this paper
• Synthesis of hemoglobin in a cell-free system. I. Properties of the complete system.

  1962cited by this paper
• Tissue sulfhydryl groups.

  1959cited by this paper

• CD38-Directed Therapies for Management of Multiple Myeloma

  2021cites this paper
• Targeted Therapy With Immunoconjugates for Multiple Myeloma

  2020cites this paper
• Early Response to the Plant Toxin Stenodactylin in Acute Myeloid Leukemia Cells Involves Inflammatory and Apoptotic Signaling

  2020cites this paper
• CD38 as an immunotherapeutic target in multiple myeloma

  2018cites this paper
• Hyperuricaemia, Xanthine Oxidoreductase and Ribosome-Inactivating Proteins from Plants: The Contributions of Fiorenzo Stirpe to Frontline Research

  2017cites this paper
• Two Saporin-Containing Immunotoxins Specific for CD20 and CD22 Show Different Behavior in Killing Lymphoma Cells

  2017cites this paper
• High in Vitro Anti-Tumor Efficacy of Dimeric Rituximab/Saporin-S6 Immunotoxin

  2016cites this paper
• Title Immuno-targeting the multifunctional CD 38 using nanobody

  2016cites this paper
• Immuno-targeting the multifunctional CD38 using nanobody

  2016cites this paper
• Plant Toxin-Based Immunotoxins for Cancer Therapy: A Short Overview

  2016cites this paper
• Immunotherapies targeting CD38 in Multiple Myeloma

  2016cites this paper
• CD38 Monoclonal Antibody Therapies for Multiple Myeloma.

  2015cites this paper
• Therapeutics , Targets , and Chemical Biology A Preclinical Model of CD 38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies

  2014cites this paper
• A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.

  2014cites this paper
• The role of CD38 expression on NAD levels and cell physiology in a leukaemia model

  2014cites this paper
• Daratumumab granted breakthrough drug status

  2014cites this paper
• Daratumumab - przełomowy lek w terapii szpiczaka plazmocytowego Daratumumab - breakthrough drug in multiple myeloma

  2014cites this paper
• Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy

  2014influential citation
• [Daratumumab--breakthrough drug in multiple myeloma therapy].

  2014cites this paper
• Saporin-S6: A Useful Tool in Cancer Therapy

  2013cites this paper
• Saporin Conjugated Monoclonal Antibody to the Transcobalamin Receptor TCblR/CD320 Is Effective in Targeting and Destroying Cancer Cells

  2013cites this paper
• Endocytosis and intracellular localisation of type 1 ribosome-inactivating protein saporin-s6.

  2012cites this paper
• Regulation of CD38 expression in human airway smooth muscle cells: role of class I phosphatidylinositol 3 kinases.

  2012cites this paper
• T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells

  2011cites this paper
• Immunotoxins and Other Conjugates Containing Saporin-S6 for Cancer Therapy

  2011cites this paper
• Synergistic and persistent effect of T‐cell immunotherapy with anti‐CD19 or anti‐CD38 chimeric receptor in conjunction with rituximab on B‐cell non‐Hodgkin lymphoma

  2010cites this paper
• Targeted Delivery of Saporin Toxin by Monoclonal Antibody to the Transcobalamin Receptor, TCblR/CD320

  2010cites this paper
• Saporin induces multiple death pathways in lymphoma cells with different intensity and timing as compared to ricin.

  2009cites this paper
• Membrane lipidomics: the reorganization of fatty acids as a biomarker of cell condition

  2009cites this paper
• ATG‐saporin‐S6 immunotoxin: a new potent and selective drug to eliminate activated lymphocytes and lymphoma cells

  2009cites this paper
• Recent progress in research on ribosome inactivating proteins.

  2009cites this paper
• Activated T–cell-mediated Immunotherapy With a Chimeric Receptor Against CD38 in B-cell Non-Hodgkin Lymphoma

  2009cites this paper
• Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology.

  2008cites this paper
• CD38 at the junction between prognostic marker and therapeutic target.

  2008cites this paper
• Atomic resolution (1.1 Å) structure of the ribosome‐inactivating protein PD‐L4 from Phytolacca dioica L. leaves

  2008cites this paper
• Enhancing the therapeutic index of radiation in multiple myeloma

  2006cites this paper